South Korea–based molecular diagnostics company Seegene is unveiling two of its most advanced innovations—CURECA™ and STAgora™—at ADLM 2025 in Chicago, marking a bold step toward redefining automation in diagnostic testing.
From July 28 to 31, Seegene will showcase the world’s first fully automated PCR system, CURECA, and its companion global data analytics platform, STAgora, in their physical forms for the first time. The launch represents the culmination of years of development focused on creating an end-to-end unmanned diagnostic solution.
CURECA automates the entire PCR testing process—from sample input to result interpretation—with no human intervention. The system successfully addresses one of the most challenging steps in lab automation: pre-processing. It can handle complex specimen types, such as stool, blood, and sputum, maintaining consistent quality while enabling continuous 24-hour operation without trained personnel.
Designed with a modular architecture, CURECA can be customized to fit various lab sizes and needs. Whether in large-scale testing facilities or small, space-constrained clinics, the system offers scalable flexibility.
Seegene’s automation technology has already attracted international attention. At ESCMID Global 2025 in Vienna last April, over 2,000 attendees from Europe and North America visited Seegene’s booth after viewing the initial concept and demo video of CURECA.
Alongside the hardware, Seegene will also debut STAgora, a cloud-based analytics platform that compiles and visualizes PCR test data generated by CURECA systems worldwide.
STAgora enables real-time analysis of infectious disease trends, co-infection patterns, and positivity rates by region. Clinicians can compare patient results with local outbreak data to enhance diagnostic precision and tailor treatment strategies accordingly.
Seegene envisions STAgora as a data-driven hub for precision medicine, connecting diagnostics to treatment pathways through intelligent, real-time insights.
The company is rapidly expanding its molecular diagnostics ecosystem. In February, it acquired DandiMecha, a robotics-based automation firm, to internalize key technologies and components. Seegene has also established U.S.-based subsidiaries—Seegene Technologies and Seegene CURECA—to enhance local R&D and manufacturing capabilities.
“CURECA and STAgora are not just devices or software—they represent a new global standard in diagnostics,” said Daniel Shin, Executive Vice President of Global Sales and Marketing at Seegene. “We’re committed to transforming the global diagnostics landscape through our accumulated technological expertise.”
